Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Stage IIB Pancreatic Cancer: early-phase trial registry

A small indexed set (3 trials) with no open enrollment listed right now.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count

Stage IIB Pancreatic Cancer: 3 US clinical trials tracked, none currently recruiting.

Stage IIB Pancreatic Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Utah, running 1 of these trials.

Enrollment posture brief

Registry condition stage-iib-pancreatic-cancer

OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Stage IIB Pancreatic Can (th…0%
Open-enrollment share among volume-matched conditions near Stage IIB Pancreatic Cancer

Stage IIB Pancreatic Cancer has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage IIB Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage IIB Pancreatic Cancer is recruiting below its size-band peers.

    0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Top Sponsors

Named interventions

Most-linked intervention names on Stage IIB Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

oxaliplatin Drug
2 trials
gemcitabine hydrochloride Drug
1 trials
irinotecan hydrochloride Drug
1 trials
leucovorin calcium Drug
1 trials
capecitabine Drug
1 trials
fluorouracil Drug
1 trials
intensity-modulated radiation therapy Radiation
1 trials
therapeutic conventional surgery Procedure
1 trials

US sites by state

Facility locations filed on Stage IIB Pancreatic Cancer trials. A trial with sites in several states counts in each.

Washington 1 trials
Utah 1 trials
Connecticut 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage IIB Pancreatic Cancer page

3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Stage IIB Pancreatic Cancer trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • University of Utah sponsors the most Stage IIB Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See University of Utah's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIB Pancreatic Cancer condition card totals 3 registered trials; most-linked intervention oxaliplatin; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.